1. Home
  2. IMRX vs SGMT Comparison

IMRX vs SGMT Comparison

Compare IMRX & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMRX
  • SGMT
  • Stock Information
  • Founded
  • IMRX 2008
  • SGMT 2006
  • Country
  • IMRX United States
  • SGMT United States
  • Employees
  • IMRX N/A
  • SGMT N/A
  • Industry
  • IMRX Biotechnology: Pharmaceutical Preparations
  • SGMT
  • Sector
  • IMRX Health Care
  • SGMT
  • Exchange
  • IMRX Nasdaq
  • SGMT Nasdaq
  • Market Cap
  • IMRX 232.9M
  • SGMT 238.7M
  • IPO Year
  • IMRX 2021
  • SGMT 2023
  • Fundamental
  • Price
  • IMRX $7.49
  • SGMT $6.65
  • Analyst Decision
  • IMRX Strong Buy
  • SGMT Strong Buy
  • Analyst Count
  • IMRX 5
  • SGMT 8
  • Target Price
  • IMRX $17.20
  • SGMT $29.75
  • AVG Volume (30 Days)
  • IMRX 1.2M
  • SGMT 492.4K
  • Earning Date
  • IMRX 11-12-2025
  • SGMT 11-13-2025
  • Dividend Yield
  • IMRX N/A
  • SGMT N/A
  • EPS Growth
  • IMRX N/A
  • SGMT N/A
  • EPS
  • IMRX N/A
  • SGMT N/A
  • Revenue
  • IMRX N/A
  • SGMT N/A
  • Revenue This Year
  • IMRX N/A
  • SGMT N/A
  • Revenue Next Year
  • IMRX N/A
  • SGMT N/A
  • P/E Ratio
  • IMRX N/A
  • SGMT N/A
  • Revenue Growth
  • IMRX N/A
  • SGMT N/A
  • 52 Week Low
  • IMRX $1.10
  • SGMT $1.73
  • 52 Week High
  • IMRX $10.08
  • SGMT $11.41
  • Technical
  • Relative Strength Index (RSI)
  • IMRX 62.47
  • SGMT 37.22
  • Support Level
  • IMRX $6.62
  • SGMT $6.32
  • Resistance Level
  • IMRX $7.50
  • SGMT $8.15
  • Average True Range (ATR)
  • IMRX 0.62
  • SGMT 0.60
  • MACD
  • IMRX 0.08
  • SGMT -0.18
  • Stochastic Oscillator
  • IMRX 91.19
  • SGMT 12.30

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: